Loading the Newsroom

The dispute centers on whether Lilly is using the most up-to-date clinical information in its marketing, and why it matters in the GLP-1 land grab.

The lawsuit alleges Lilly's Zepbound and Mounjaro marketing leans on stale evidence to exaggerate efficacy versus rivals.

A court filing asks to block Lilly’s GLP-1 advertising and force corrections, raising the heat on drug marketing scrutiny.